v3.26.3
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities:    
Net loss $ (14,127,610) $ (23,970,277)
Adjustments to reconcile net loss to net cash from operating activities:    
Net unrealized gain on equity securities at fair value (790,405) (49,407)
Net (income) loss from equity method investments at fair value (421,696) 767,066
Net realized gain on investments (24,302) (132,434)
Impairment loss on assets held for sale 1,687,783 0
Impairment loss 0 9,500,167
Straight-line rent (205,958) (154,952)
Depreciation and amortization 9,141,627 11,432,557
Amortization of deferred financing costs and debt mark-to-market 1,367,580 1,377,272
Accretion of above (below) market lease, net (161,645) (544,103)
Stock-based compensation 37,363 628,137
Changes in assets and liabilities:    
Investments income, rents and other receivables (514,243) (890,103)
Prepaid expenses and other assets 137,361 125,104
Deferred rent and other liabilities (13,123) 50,398
Accounts payable and accrued liabilities (1,092,443) 144,376
Due to related entities 1,670,483 26,097
Net cash from operating activities (3,309,228) (1,690,102)
Cash flows from investing activities:    
Proceeds from sale of investments 3,709,739 962,721
Investments in real estate assets (9,149,758) (18,899,433)
Purchase of investments (3,695,650) (1,183,597)
Net cash from investing activities (9,135,669) (19,120,309)
Cash flows from financing activities:    
Borrowing under mortgage notes payable 22,803,277 48,477,670
Payments on mortgage notes payable (11,662,553) (48,876,780)
Borrowing under line of credit 412,000 9,588,000
Proceeds from notes payable 3,625,438 1,115,000
Payments on notes payable (2,047,342) (223,898)
Payment of financing fees (918,460) (2,321,155)
Dividends to common stockholders 0 (4,802,866)
Proceeds from issuance of common stock 317,121 3,794,260
Proceeds from issuance of pre-funded warrants 0 1,935,455
Payment on finance lease liabilities (274,028) (234,109)
Payment of selling commissions and fees (381,324) (1,876,917)
Contributions by non-controlling interests holders 0 5,574,804
Distributions to non-controlling interests holders (1,527,214) (1,491,165)
Redemptions of common stock (1,784) (24)
Capital pending acceptance (13,411) (283,589)
Net cash from financing activities 12,137,311 11,849,393
Net decrease in cash, cash equivalents and restricted cash (307,586) (8,961,018)
Cash, cash equivalents and restricted cash at beginning of the year 4,116,321 13,077,339
Cash, cash equivalents and restricted cash at end of the year 3,808,735 4,116,321
Cash and cash equivalents at end of the year 3,517,313 3,627,360
Restricted cash at end of the year 202,886 328,239
Cash at end of the year classified as assets held for sale 88,536 160,722
Total cash, cash equivalents, restricted cash and cash classified as held for sale at end of the year 3,808,735 4,116,321
Supplemental disclosure of non-cash financing activities and other cash flow information:    
Cash paid for interest 7,990,528 7,203,282
Conversion of Operating Partnership Series A Preferred Units to common stock 118,082 0
Reclassification of prepaid expenses and other assets to mortgage notes payable, net 294,042 0
Capitalized construction in progress outstanding as accounts payable and accrued expenses 0 1,912,673
Stock-based compensation 0 665,500
Operating Partnership Class A conversion to common stock 0 3,301
Green Valley Medical Center, LP [Member]    
Supplemental disclosure of non-cash financing activities and other cash flow information:    
Issuance of the Operating Partnership Preferred Units for the purchase of Green Valley Medical Center, LP (Note 1) 0 2,712,194
Fair value of assets acquired from consolidation of Green Valley Medical Center, LP 0 13,621,753
Fair value of liabilities assumed from consolidation of Green Valley Medical Center, LP 0 8,904,457
Martin Plaza Associates, LP [Member]    
Supplemental disclosure of non-cash financing activities and other cash flow information:    
Conversion of notes receivable to preferred equity of Martin Plaza Associates, LP 0 200,000
Series A Preferred Stock [Member]    
Cash flows from financing activities:    
Dividends to preferred stockholders (943,328) (952,669)
Proceeds from issuance of preferred stock 1,164,985 226,100
Redemptions of preferred stock (88) (5,531)
Supplemental disclosure of non-cash financing activities and other cash flow information:    
Issuance of preferred stock through reinvestment of dividends 187,418 192,770
Issuance of Operating Partnership Preferred Units - Series A through reinvestment of dividends 112,134 98,968
Preferred Series conversion to common stock 2,301,515 318,161
Series B Preferred Stock [Member]    
Cash flows from financing activities:    
Dividends to preferred stockholders (63,393) (40,449)
Proceeds from issuance of preferred stock 332,488 1,647,579
Redemptions of preferred stock (13) 0
Supplemental disclosure of non-cash financing activities and other cash flow information:    
Issuance of preferred stock through reinvestment of dividends 25,697 14,503
Increase in liquidation preference of Series B preferred stock 273,582 204,889
Increase in liquidation preference of Operating Partnership Preferred Units - Series B 97,227 97,229
Preferred Series conversion to common stock 151,462 0
Conversion of Series B preferred stock liquidation preference (9% non-cash dividend) to common stock 8,804 0
Series C Preferred Stock [Member]    
Cash flows from financing activities:    
Dividends to preferred stockholders (51,060) 0
Proceeds from issuance of preferred stock 1,366,000 0
Supplemental disclosure of non-cash financing activities and other cash flow information:    
Issuance of preferred stock through reinvestment of dividends 1,508 0
Series A Common Stock [Member]    
Cash flows from financing activities:    
Proceeds from issuance of common stock warrants 0 376,268
Series B Common Stock [Member]    
Cash flows from financing activities:    
Proceeds from issuance of common stock warrants $ 0 $ 223,409